Phibro Animal Health Corp (PAHC) Q2 2026 Earnings Call

Concluded Feb 5, 2026

Feb 5, 2026 0 turns

Period: FY2026 Q2
Runtime: —
Sources: 3 artifacts

Slides 11 8-K 10-Q

Executive readout · one minute

Webcast research workspace

Read the call alongside every captured source. slides, 8-K earnings release, 10-Q stay in one workspace.

Animal health segment growth and MFA integration 38 Phibro Forward cost and margin initiatives 18 Raised full-year guidance 13 Quarterly results and adjusted EBITDA growth 12 Protein market conditions and customer demand 11 Leadership transition 10

Management tone

Confident

Net tone +75 · low hedging

Grounding quotes

“we delivered 26% growth in animal health sales and a 41% increase in Animal Health adjusted EBITDA. A clear sign our strategy is working.”
“we are raising both our full-year sales and earnings guidance”
“Taken together with our financial performance, Barcelona and IPPE make it clear that Phibro has real sustainable momentum.”
“Producer confidence is rising, and global demand remains resilient.”

Research coverage

3 live sources

Open each available source without leaving this research workspace.

Revenue $373.91M +20.9% YoY

Diluted EPS $0.67 +737.5% YoY

Gross margin 35.5% +2.6 pp YoY

Net income $27.46M +762.1% YoY

Research materials

Open the source you need; every reader stays inside this workspace.

Presentation 11 pages 8-K earnings release Filed Feb 4, 2026 10-Q report Filed Feb 4, 2026 Company webcastOpen the original investor-relations page

Quarter detail

How the reported period landed and where the business moved.

Revenue · segments

Animal Health$289.98M +26.4% YoY

Mineral Nutrition$68.94M +9% YoY

Performance Products$14.99M -9.7% YoY

Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →